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Research on mitochondria in the last years has been characterized by the fundamental
finding that the morphology of mitochondria is deeply connected to the regulation of a vast
number of different processes, including oxidative phosphorylation and ATP production,
calcium buffering, and apoptosis. This has immediately focused the attention of the
neuroscience community to the possible involvement of mitochondrial dynamism, the
process underlying morphological features of mitochondria, in neurodegeneration, where
mitochondrial dysfunction is believed to represent an important contributing event, or even
a primary causative factor. Amyotrophic Lateral Sclerosis (ALS), a disease of motor neurons
and their neighboring cells, has long been considered as a neurodegenerative disease with
an important mitochondrial issue. Yet, whether mitochondria have a causative, primary
role in the pathogenic process has always been debated, and the specific defects which
account for this role are elusive. Here we discuss recent genetic advances suggesting that
defective mitochondrial dynamism is primarily involved in the pathogenic mechanisms of
ALS, and that foster the longstanding concept that disruption of mitochondrial function is
a vulnerable factor for motor neurons.
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INTRODUCTION
Demise of motor neurons in the spinal cord, brain cortex, and
brainstem of patients is responsible for Amyotrophic Lateral
Sclerosis (ALS). Degeneration of motor neurons has been
considered for a long time the most significant feature of
ALS. However, since the discovery of the first gene responsible
for familial forms of ALS, Sod1, many fundamental advances
in our knowledge of the disease have been reached, and the
comprehension of the biological, genetic and clinical processes
underlying ALS, has impressively increased (Cozzolino et al.,
2012). According to these findings, the current thinking is that
ALS is a complex multi-systemic and multi-factorial syndrome
and that motor neuron degeneration is only part of a more
widespread and multifaceted disease process. Different lines of
evidence support this concept. First, ALS appears as a multi-
systemic disease, where different tissues and cell types, such as
astrocytes and microglia, oligodendrocytes and muscles cells,
among others, are both targeted by the disease processes and
actively participate to the final disease outcome (Robberecht and
Philips, 2013). Second, a number of genes have been identified
so far that are definitely associated to ALS pathogenesis and that
now cover a large fraction of the familial cases of the disease
(Renton et al., 2014). According to their known biological role,
or to new acquired functions as a consequence of gene mutations,
they are apparently connected to different physiological processes,
implying that diverse pathogenic mechanisms, not necessarily
related, might be involved in ALS onset and progression.
Indeed, robust experimental evidence showing that RNA dys-
regulation, protein misfolding, oxidative damage, defective axonal
transport and excitotoxicity are actively implicated in ALS has
accumulated from studies in experimental models as well as
tissue samples and iPSC-derived neural cells from patients
(Cozzolino et al., 2012). Third, many of the same gene mutations
that are definitely involved in familial forms of ALS (and
even in apparently sporadic forms, which represent the vast
majority of ALS cases) have been also described as associated
to diseases that do not primarily manifest with motor neuronal
phenotypes, and in particular to Fronto Temporal Dementia
(FTD; Cooper-Knock et al., 2014), strengthening the complex
character of the disease and the consequent variability in its
phenotypic expression, which is now well recognized (Swinnen
and Robberecht, 2014).
In the very last years, the major focus of ALS research has
moved to RNA control of motor neuron functions, as most of the
newly identified genes are more or less directly associated to RNA
regulation. These include FUS/TLS and TDP-43, two DNA/RNA
binding proteins with an established, yet not completely clear,
role in the regulation of RNA transcription, splicing, transport
and translation, and C9orf72, a gene that is profoundly affected
by the presence, in carriers, of an highly expanded GGGGCC
repeat: it is widely believed that this repeat provides the mutant
gene of an acquired, toxic feature by an RNA-dependent gain
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of function mechanism (Achsel et al., 2013). Since these three
genes alone account for more than half of ALS familial cases,
RNA dys-metabolism is likely to represent a central issue in ALS
pathogenesis. Yet, as we will discuss in the next paragraphs, recent
genetic evidence put mitochondria, an old player in ALS research,
under the spotlight once again.
MITOCHONDRIA INVOLVEMENT IN ALS: FUNCTIONAL
EVIDENCE AND TRAITS OF AN (UN)RESOLVED ISSUE
Mitochondrial dysfunction has always been recognized as
a candidate major player in ALS pathogenesis. Abnormal
mitochondrial structure, alterations in the electron transport
by mitochondrial complexes I-IV, defects in the import of
mitochondrial proteins, to cite just some of the key features
of mitochondria, have been found in ALS models and patients
(for comprehensive reviews, see Cozzolino and Carrì, 2012; Tan
et al., 2014). As a result, cellular energy imbalance, increased
oxidative stress, induction of apoptosis, and impaired calcium
handling (all traits that have been frequently observed in
cell, animal models, and, as far as it is possible, also in
patients) have been considered as likely direct consequences
of mitochondrial dys-functioning. Most notably, many of these
mitochondrial defects can be clearly detected much before the
onset of symptoms, arguing for a primary role of mitochondria
in the disease determination. Even some of the proteins that
are definitely responsible for, or at least associated to familial
ALS cases, have been described to possess mitochondria-related
function. This is the case of SOD1, a protein with a prevalent
steady state cytosolic localization, and with a small fraction
localized in the intermembrane space of mitochondria, where it
possibly exerts an antioxidant function; VAPB, an endoplasmic
reticulum (ER)-resident protein that regulate ER-mitochondria
interaction; and optineurin, that is recruited to damaged
mitochondria that are then targeted to the mitophagic process
underlying mitochondria recycling. ALS associated mutations
are believed to either disrupt these functions, as in the case
of VAPB and optineurin, or to confer new functions that are
detrimental to mitochondria, as in the case of SOD1 and TDP43
(Cozzolino et al., 2013; Stoica et al., 2014; Wong and Holzbaur,
2014).
Yet, clinical testing of mitochondrial protecting drugs was in
no instance able to provide some beneficial effect to patients,
although positive outcomes could be predicted by the effects that
the same drugs exerted on ALS models (Mitsumoto et al., 2014;
Poppe et al., 2014). Even preclinical genetic approaches aimed at
supporting a causal role for mitochondrial function disturbance
in ALS gave conflicting results. For example, preserving spinal
cord mitochondrial function by removal of p66Shc, a key
regulator of mitochondrial oxidative balance, provided a very
significant delay in both disease onset and life span of G93A-
SOD1 mice (Pesaresi et al., 2011). However, when mitochondrial
function was robustly restored by increasing the calcium-
buffering activity of mitochondria through cyclophylin D knock-
out, no significant effect on muscle denervation, motor axon
degeneration, disease progression and survival was observed,
questioning whether mitochondria do indeed participate to the
disease (Parone et al., 2013).
In view of the key role of morphology regulation in
determining the functional state of the mitochondria, and
considering that dysfunctions in this process are clearly associated
to neurodegeneration (Chen and Chan, 2009), including motor
neuron degeneration (Züchner et al., 2004), it is not surprising
that a number of efforts have been made to ascertain whether
mitochondrial dynamism defects could be involved in ALS
disease. This has been essentially performed in cell and animal
models based on mutant SOD1s expression, but other disease
models that express newly identified ALS genes have been tested
as they became available.
Fusion and fission are responsible for the overall structure
of mitochondria. The two processes are highly coordinated
and strictly controlled by a series of dedicated proteins, whose
number is continuously increasing. The balance between the
activity of fusion and fission proteins thus determines the
shaping of the mitochondrial network, which in turn has a
central role in mitochondrial function in all tissues, including
the nervous tissue (Itoh et al., 2013; da Silva et al., 2014).
A clear fragmented mitochondrial network is induced by the
expression of different SOD1 mutants in a variety of cellular
models, including rat spinal cord motor neurons (Magrané
et al., 2009; Ferri et al., 2010; Pesaresi et al., 2011; Song et al.,
2013). Accordingly, the expression of the pro-fusion proteins
Mfn1 and Opa1, and the pro-fission proteins Drp-1 and Fis-
1, is respectively decreased, or maintained at high levels during
the disease course that characterizes mutant SOD1 mice (Liu
et al., 2013). Importantly, preservation of mitochondrial function
by overexpression of PGC-1alpha, Sirtuin-3 or Glutaredoxin-
2, three proteins that are known to regulate intracellular ROS
balance and mitochondrial energy metabolism, restores a correct
mitochondrial network, as well as the steady state expression
levels of mitochondrial dynamism proteins (Ferri et al., 2010;
Song et al., 2013). Therefore, also in ALS an imbalance
between fusion/fission regulation might well be involved in
mitochondrial dysfunction. Most notably, overexpression of a
dominant negative form of DRP1 which lacks the GTPase
activity and thus blocks mitochondrial fission, is able to
inhibit mitochondrial fragmentation and cell death in cortical
neurons expressing mutant SOD1, indicating that, at least in
this experimental system, a causal link exists between defects
in the fusion/fission process and the functional and structural
mitochondrial alterations (Song et al., 2013).
A bulk of experimental evidence has indicated important
functional links between the dynamism of mitochondria and
their transport along axons, and this concept also emerged
from studies where mitochondrial morphology alterations and
mitochondrial transport have been analyzed in the context of
ALS-related cultured cells and mouse models. Impairment of
axonal transport of mitochondria is an early event in mice
overexpressing ALS-linked mutant forms of SOD1 or wild-
type and mutant TDP43, all mimicking, to different degrees,
the disease (De Vos et al., 2007; Wang et al., 2013; Magrané
et al., 2014). This process is related to a clear alteration in
mitochondrial morphology, with mitochondria of transgenic
mice appearing shorter in length and fragmented. Further, it
seems to be specific for motor neurons, as it is recognizable in
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the ventral roots motor axons, but not in sensory neurons of the
dorsal roots (Magrané et al., 2014). In the G93A-SOD1 mouse,
in particular, this event is already evident at 15 days of age,
suggesting that an early fragmentation of mitochondria might
underlie retrograde transport defects. Interestingly, early, pre-
symptomatic defects in mitochondrial transport and morphology
were also observed in the skeletal muscle of G93A-SOD1
overexpressing mice. Interestingly, inhibition of mitochondrial
fission by a Drp-1 inhibitor restored both mitochondrial
network and transport (Luo et al., 2013), thus extending
to muscle cells, that might well play an important role in
ALS pathogenesis, the relevance of mitochondrial dynamics
defects. In an A315T-TDP43 transgenic mouse, however,
mitochondrial fragmentations seems to occur significantly
later than mitochondrial transport defects, suggesting the
existence of alternative mechanisms accounting for mitochondrial
dysfunction in the two mouse models (Magrané et al., 2014).
Yet, when cultured motor neurons were transfected with both
wild-type and the M333V ALS-linked mutant of TDP-43 in the
presence of an overexpressed Mfn2, a rescue in both length
and density of mitochondria was observed and their transport
along axons and dendrites recovered (Wang et al., 2013). On
these grounds, it is therefore clear that mitochondria alterations,
including defective mitochondrial dynamics, are tightly linked to
ALS pathogenesis.
MITOCHONDRIA INVOLVEMENT IN ALS: GENETIC EVIDENCE
OPEN A NEW SCENARIO
Nevertheless, whether mitochondria have a causative, primary
role in the disease has always been debated. Recent experimental
evidence, however, has provided significant genetic basis to
support the conclusion that mitochondria degeneration is
deeply involved in the pathogenic mechanisms, at least in
some forms of the disease, and more generally, that motor
neurons are particularly vulnerable to defective mitochondrial
function.
In a screening of muscle biopsies from patients belonging to
a family that presented late-onset myopathy, coupled to motor
and cognitive phenotypes, including motor neuron disease and
FTD-like symptoms, Bannwarth et al. have identified a missense
mutation (S59L) in the nuclear CHCHD10 gene, which encodes
for a mitochondrial-resident protein (Bannwarth et al., 2014).
An identical missense mutation was pinpointed by the same
authors in a screening of 21 families characterized by ALS/FTD
phenotypes, leading to the hypothesis that variations in the
CHCHD10 gene is a cause of ALS and FTD. These findings
promptly led the same group, as well as other labs, to screen
for variants in CHCHD10 gene in the ALS/FTD population.
Results from these screenings confirmed the existence of this
variant in different ALS pedigrees (Chaussenot et al., 2014;
Johnson et al., 2014; Müller et al., 2014). Further, three novel
mutations (R15L, P34S and G66V) were identified in patients
with ALS/FTD or ALS only, which strengthened the connection
between CHCHD10 mutations and these diseases (Chaussenot
et al., 2014; Johnson et al., 2014; Müller et al., 2014). Interestingly,
a double missense mutation (R15S/G85R) in the coding
region of CHCHD10 has been identified in patients suffering
from autosomal dominant mitochondrial myopathy, a disease
characterized by morphological and biochemical alterations of
mitochondria (Ajroud-Driss et al., 2015). Thus, mitochondrial
function could be profoundly affected by mutations in this gene,
independently from the tissue affected.
Although further analysis in larger populations is needed to
confirm the frequency of these mutations in the familial/sporadic
ALS population, and to make the genetic link between
CHCHD10 and ALS more robust (van Rheenen et al.,
2014), these findings might represent a landmark discovery
in ALS research, because for the first time a gene coding
for a mitochondrial protein has been identified as a possible
cause for the disease, which eventually implies mitochondrial
dysfunction as a primary trigger of ALS. Furthermore, they
also provide additional circumstantial evidence that alteration
in mitochondrial dynamism is involved in ALS pathogenesis.
Indeed, although the function of CHCHD10 protein is still
almost uncharacterized, preliminary experiments and structural
analogies with proteins of the CHCH family suggest that it
might be involved in the regulation of mitochondrial function in
general, and in mitochondria morphology processes in particular.
CHCHD10 shows a prominent mitochondrial localization
(Bannwarth et al., 2014; Ajroud-Driss et al., 2015), and
sub-mitochondrial fractionation coupled to protease digestion
showed that CHCHD10 is located in the intermembrane space
of mitochondria (Bannwarth et al., 2014). Overexpression
of the mutant S59L-CHCHD10 in HeLa cells profoundly
affected mitochondrial structure, inducing a clear fragmented
morphology with disorganization of cristae structure and matrix
condensation (Bannwarth et al., 2014). This observation is in
line with the effect that the G58R mutant found in autosomal
dominant mitochondrial myopathy patients produced in cultured
human cells (Ajroud-Driss et al., 2015), suggesting that the
mitochondria-induced morphological defects that distinguish
CHCHD10 mutations are a common trait of highly metabolic
tissues such as muscle and the nervous system.
As the others members of the CHCH protein family,
CHCHD10 contains a coiled coil-helix-coiled coil-helix (CHCH)
fold that is stabilized by disulfide bonds formed by twin CX(9)C
motifs (Figure 1). The CXnC motif has emerged as a central
attribute underlying the import in mitochondria of proteins
lacking canonical organelle targeting signals. The mechanism
has been characterized in detail: cysteine-containing motifs are
targeted by the mitochondrial intermembrane space assembly
(MIA) machinery, that oxidizes cysteine residues, and drive the
electrons from reduced and unfolded proteins to the respiratory
chain. As a result, proteins reach their folded, oxidized state
and are entrapped inside the intermembrane space. The reaction
is carried on through the intervention of an oxidoreductase,
MIA40, and a sulphhydryl oxidase, Erv1 (Mesecke et al., 2005).
Since the redox milieu of mitochondria is clearly altered in ALS
conditions (Ferri et al., 2006), it is tempting to speculate that
either mutations in the gene, or alteration in the mitochondrial
redox balance might affect the proper mitochondrial import
of CHCHD10, eventually leading to mitochondria dysfunction.
However, the mutations in CHCHD10 that have been described
so far do not seem to alter the mitochondrial localization of the
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FIGURE 1 | Structural features of CHCHD10. Four exons of the human
CHCHD10 gene encode for a 142 aa mature protein. A coiled helix coiled
helix domain (CHCH) is present in the C-terminal half of the polypeptide. A
twin CX9C domain, which is targeted by the Mia40/Erv1 mechanism of
oxidative import of mitochondrial proteins, is also present. A putative
mitochondrial targeting sequence in the N-terminus, and a central
hydrophobic helix have been also described. Mutations associated to
ALS/FTD phenotypes (red triangles) and to Autosomal Dominant
Mitochondrial Miopathy (ADMM, purple triangles) are reported. They all fall
in the second exon.
protein (Bannwarth et al., 2014; Ajroud-Driss et al., 2015), which
is in agreement to the fact that these mutations do not fall into
the CHCH domain nor in a putative N-terminal mitochondrial
localization signal, that is predicted by bioinformatical analysis
(Figure 1).
Although a more detailed analysis of mitochondrial
localization of the mutant protein is needed, it is reasonable
to imagine that the impaired mitochondrial function by mutant
CHCHD10 is consequent to an altered protein function, which is
to date still unknown. Circumstantial evidence suggest that this
function might be closely related to the control of mitochondrial
morphology and the fusion/fission process. Indeed, mutant
CHCHD10 overexpression in HeLa cells altered mitochondrial
shape, inducing a fragmented phenotype, as already mentioned.
Moreover, immunoelectron microscopy showed that CHCHD10
is located in close proximity of mitochondrial cristae junctions,
and overexpression of the S59L mutant induced cristae
loss, disorganization and dilation (Bannwarth et al., 2014).
Further, CHCHD3, a member belonging to the same CHCH
mitochondrial family of proteins, has a possible function in the
regulation of cristae morphology as well (Darshi et al., 2011),
and cristae shape is tightly linked to the assembly of respiratory
chain complexes into quaternary supercomplexes that represent
the functional mitochondrial respiratory units (Acín-Pérez et al.,
2008; Cogliati et al., 2013). Accordingly, CHCHD3 interacts
with OPA1, and down-regulation of CHCHD3 in HeLa cells
resulted in fragmentation of the mitochondrial network and a
significant remodeling of the cristae architecture, two functions
that OPA1 controls through independent mechanisms (Frezza
et al., 2006). Interestingly, CHCHD3 is significantly decreased in
NSC34 motor neuron-like cells overexpressing a mutant SOD1
that is associated to familial ALS, further suggesting a possible
wider role of CHCH-containing family of mitochondrial proteins
in the pathogenesis of the disease (Fukada et al., 2004).
In conclusion, a renewed interest to altered mitochondria
physiology in ALS comes from genetic evidence of a link
between an ALS/FTD phenotype in patients and mutations in
CHCHD10 gene. Further studies are needed to assess whether an
altered mitochondrial dynamism is a cause or a consequence of
mitochondrial functional derangement, whether it is common to
all forms of ALS and whether interventions aimed to restore a
correct dynamism may represent a therapeutic option.
ACKNOWLEDGMENTS
Maria Teresa Carrì is supported by ARiSLA (Project OligoALS)
and by the Bruno and Ilse Frick Foundation for ALS research 2012
Award; Mauro Cozzolino is supported by Ministero della Salute
(Project RF-2010-2309849) and by AriSLA (Project FUSMALS).
REFERENCES
Achsel, T., Barabino, S., Cozzolino, M., and Carrì, M. T. (2013). The intriguing case
of motor neuron disease: ALS and SMA come closer. Biochem. Soc. Trans. 41,
1593–1597. doi: 10.1042/BST20130142.
Acín-Pérez, R., Fernández-Silva, P., Peleato, M. L., Pérez-Martos, A., and Enriquez,
J. A. (2008). Respiratory active mitochondrial supercomplexes. Mol. Cell 32,
529–539. doi: 10.1016/j.molcel.2008.10.021
Ajroud-Driss, S., Fecto, F., Ajroud, K., Lalani, I., Calvo, S. E., Mootha, V. K.,
et al. (2015). Mutation in the novel nuclear-encoded mitochondrial protein
CHCHD10 in a family with autosomal dominant mitochondrial myopathy.
Neurogenetics 16, 1–9. doi: 10.1007/s10048-014-0421-1
Bannwarth, S., Ait-El-Mkadem, S., Chaussenot, A., Genin, E. C., Lacas-Gervais, S.,
Fragaki, K., et al. (2014). A mitochondrial origin for frontotemporal dementia
and amyotrophic lateral sclerosis through CHCHD10 involvement. Brain 137,
2329–2345. doi: 10.1093/brain/awu138
Chaussenot, A., Le Ber, I., Ait-El-Mkadem, S., Camuzat, A., de Septenville, A.,
Bannwarth, S., et al. (2014). Screening of CHCHD10 in a French cohort
confirms the involvement of this gene in frontotemporal dementia with
amyotrophic lateral sclerosis patients. Neurobiol. Aging 35, 2884.e1–2884.e4.
doi: 10.1016/j.neurobiolaging.2014.07.022
Chen, H., and Chan, D. C. (2009). Mitochondrial dynamics–fusion, fission,
movement and mitophagy–in neurodegenerative diseases. Hum. Mol. Genet. 18,
R169–R176. doi: 10.1093/hmg/ddp326
Cogliati, S., Frezza, C., Soriano, M. E., Varanita, T., Quintana-Cabrera, R., Corrado,
M., et al. (2013). Mitochondrial cristae shape determines respiratory chain
supercomplexes assembly and respiratory efficiency. Cell 155, 160–171. doi: 10.
1016/j.cell.2013.08.032
Frontiers in Cellular Neuroscience www.frontiersin.org February 2015 | Volume 9 | Article 31 | 4
Cozzolino et al. Mitochondrial dynamism in ALS
Cooper-Knock, J., Shaw, P. J., and Kirby, J. (2014). The widening spectrum
of C9ORF72-related disease; genotype/phenotype correlations and potential
modifiers of clinical phenotype. Acta Neuropathol. 127, 333–345. doi: 10.
1007/s00401-014-1251-9
Cozzolino, M., and Carrì, M. T. (2012). Mitochondrial dysfunction in ALS. Prog.
Neurobiol. 97, 54–66. doi: 10.1016/j.pneurobio.2011.06.003
Cozzolino, M., Ferri, A., Valle, C., and Carrì, M. T. (2013). Mitochondria and ALS:
implications from novel genes and pathways. Mol. Cell. Neurosci. 55, 44–49.
doi: 10.1016/j.mcn.2012.06.001
Cozzolino, M., Pesaresi, M. G., Gerbino, V., Grosskreutz, J., and Carrì, M. T.
(2012). Amyotrophic lateral sclerosis: new insights into underlying molecular
mechanisms and opportunities for therapeutic intervention. Antioxid. Redox.
Signal 17, 1277–1330. doi: 10.1089/ars.2011.4328
Darshi, M., Mendiola, V. L., Mackey, M. R., Murphy, A. N., Koller, A., Perkins,
G. A., et al. (2011). ChChd3, an inner mitochondrial membrane protein, is
essential for maintaining crista integrity and mitochondrial function. J. Biol.
Chem. 286, 2918–2932. doi: 10.1074/jbc.m110.171975
da Silva, A. F., Mariotti, F. R., Máximo, V., and Campello, S. (2014). Mitochondria
dynamism: of shape, transport and cell migration. Cell. Mol. Life Sci. 71, 2313–
2324. doi: 10.1007/s00018-014-1557-8
De Vos, K. J., Chapman, A. L., Tennant, M. E., Manser, C., Tudor, E. L., Lau,
K. F., et al. (2007). Familial amyotrophic lateral sclerosis-linked SOD1 mutants
perturb fast axonal transport to reduce axonal mitochondria content.Hum.Mol.
Genet. 16, 2720–2728. doi: 10.1093/hmg/ddm226
Ferri, A., Cozzolino, M., Crosio, C., Nencini, M., Casciati, A., Gralla, E. B., et al.
(2006). Familial ALS-superoxide dismutases associate with mitochondria and
shift their redox potentials. Proc. Natl. Acad. Sci. U S A 103, 13860–13865.
doi: 10.1073/pnas.0605814103
Ferri, A., Fiorenzo, P., Nencini, M., Cozzolino, M., Pesaresi, M. G., Valle,
C., et al. (2010). Glutaredoxin 2 prevents aggregation of mutant SOD1 in
mitochondria and abolishes its toxicity. Hum. Mol. Genet. 19, 4529–4542.
doi: 10.1093/hmg/ddq383
Frezza, C., Cipolat, S., Martins de Brito, O., Micaroni, M., Beznoussenko,
G. V., Rudka, T., et al. (2006). OPA1 controls apoptotic cristae remodeling
independently from mitochondrial fusion. Cell 126, 177–189. doi: 10.1016/j.cell.
2006.06.025
Fukada, K., Zhang, F., Vien, A., Cashman, N. R., and Zhu, H. (2004). Mitochondrial
proteomic analysis of a cell line model of familial amyotrophic lateral sclerosis.
Mol. Cell. Proteomics 3, 1211–1223. doi: 10.1074/mcp.m400094-mcp200
Itoh, K., Nakamura, K., Iijima, M., and Sesaki, H. (2013). Mitochondrial dynamics
in neurodegeneration. Trends Cell Biol. 23, 64–71. doi: 10.1016/j.tcb.2012.10.006
Johnson, J. O., Glynn, S. M., Gibbs, J. R., Nalls, M. A., Sabatelli, M., Restagno, G.,
et al. (2014). Mutations in the CHCHD10 gene are a common cause of familial
amyotrophic lateral sclerosis. Brain 137:e311. doi: 10.1093/brain/awu265
Liu, W., Yamashita, T., Tian, F., Morimoto, N., Ikeda, Y., Deguchi, K., et al. (2013).
Mitochondrial fusion and fission proteins expression dynamically change in a
murine model of amyotrophic lateral sclerosis. Curr. Neurovasc. Res. 10, 222–
230. doi: 10.2174/15672026113109990060
Luo, G., Yi, J., Ma, C., Xiao, Y., Yi, F., Yu, T., et al. (2013). Defective mitochondrial
dynamics is an early event in skeletal muscle of an amyotrophic lateral sclerosis
mouse model. PLoS One 8:e82112. doi: 10.1371/journal.pone.0082112
Magrané, J., Cortez, C., Gan, W. B., and Manfredi, G. (2014). Abnormal
mitochondrial transport and morphology are common pathological
denominators in SOD1 and TDP43 ALS mouse models. Hum. Mol. Genet. 23,
1413–1424. doi: 10.1093/hmg/ddt528
Magrané, J., Hervias, I., Henning, M. S., Damiano, M., Kawamata, H., and
Manfredi, G. (2009). Mutant SOD1 in neuronal mitochondria causes toxicity
and mitochondrial dynamics abnormalities. Hum. Mol. Genet. 18, 4552–4564.
doi: 10.1093/hmg/ddp421
Mesecke, N., Terziyska, N., Kozany, C., Baumann, F., Neupert, W., Hell, K., et al.
(2005). A disulfide relay system in the intermembrane space of mitochondria
that mediates protein import. Cell 121, 1059–1069. doi: 10.1016/j.cell.2005.
04.011
Mitsumoto, H., Brooks, B. R., and Silani, V. (2014). Clinical trials in amyotrophic
lateral sclerosis: why so many negative trials and how can trials be improved?
Lancet Neurol. 13, 1127–1138. doi: 10.1016/s1474-4422(14)70129-2
Müller, K., Andersen, P. M., Hübers, A., Marroquin, N., Volk, A. E., Danzer,
K. M., et al. (2014). Two novel mutations in conserved codons indicate that
CHCHD10 is a gene associated with motor neuron disease. Brain 137:e309.
doi: 10.1093/brain/awu227
Parone, P. A., Da Cruz, S., Han, J. S., McAlonis-Downes, M., Vetto, A. P., Lee,
S. K., et al. (2013). Enhancing mitochondrial calcium buffering capacity reduces
aggregation of misfolded SOD1 and motor neuron cell death without extending
survival in mouse models of inherited amyotrophic lateral sclerosis. J. Neurosci.
33, 4657–4671. doi: 10.1523/JNEUROSCI.1119-12.2013
Pesaresi, M. G., Amori, I., Giorgi, C., Ferri, A., Fiorenzo, P., Gabanella, F.,
et al. (2011). Mitochondrial redox signalling by p66Shc mediates ALS-like
disease through Rac1 inactivation. Hum. Mol. Genet. 20, 4196–4208. doi: 10.
1093/hmg/ddr347
Poppe, L., Rué, L., Robberecht, W., and Van Den Bosch, L. (2014). Translating
biological findings into new treatment strategies for amyotrophic lateral
sclerosis (ALS). Exp. Neurol. 262, 138–151. doi: 10.1016/j.expneurol.2014.
07.001
Renton, A. E., Chiò, A., and Traynor, B. J. (2014). State of play in amyotrophic
lateral sclerosis genetics. Nat. Neurosci. 17, 17–23. doi: 10.1038/nn.3584
Robberecht, W., and Philips, T. (2013). The changing scene of amyotrophic lateral
sclerosis. Nat. Rev. Neurosci. 14, 248–264. doi: 10.1038/nrn3430
Song, W., Song, Y., Kincaid, B., Bossy, B., and Bossy-Wetzel, E. (2013).
Mutant SOD1G93A triggers mitochondrial fragmentation in spinal cord motor
neurons: neuroprotection by SIRT3 and PGC-1α. Neurobiol. Dis. 51, 72–81.
doi: 10.1016/j.nbd.2012.07.004
Stoica, R., De Vos, K. J., Paillusson, S., Mueller, S., Sancho, R. M., Lau, K. F.,
et al. (2014). ER-mitochondria associations are regulated by the VAPB-PTPIP51
interaction and are disrupted by ALS/FTD-associated TDP-43. Nat. Commun.
5:3996. doi: 10.1038/ncomms4996
Swinnen, B., and Robberecht, W. (2014). The phenotypic variability of amyotrophic
lateral sclerosis. Nat. Rev. Neurol. 10, 661–670. doi: 10.1038/nrneurol.
2014.184
Tan, W., Pasinelli, P., and Trotti, D. (2014). Role of mitochondria in mutant SOD1
linked amyotrophic lateral sclerosis. Biochim. Biophys. Acta 1842, 1295–1301.
doi: 10.1016/j.bbadis.2014.02.009
van Rheenen, W., Diekstra, F. P., van den Berg, L. H., and Veldink, J. H. (2014).
Are CHCHD10 mutations indeed associated with familial amyotrophic lateral
sclerosis? Brain 137:e313. doi: 10.1093/brain/awu299
Wang, W., Li, L., Lin, W. L., Dickson, D. W., Petrucelli, L., Zhang, T., et al. (2013).
The ALS disease-associated mutant TDP-43 impairs mitochondrial dynamics
and function in motor neurons. Hum. Mol. Genet. 22, 4706–4719. doi: 10.
1093/hmg/ddt319
Wong, Y. C., and Holzbaur, E. L. (2014). Optineurin is an autophagy receptor for
damaged mitochondria in parkin-mediated mitophagy that is disrupted by an
ALS-linked mutation. Proc. Natl. Acad. Sci. U S A 111, E4439–E4448. doi: 10.
1073/pnas.1405752111
Züchner, S., Mersiyanova, I. V., Muglia, M., Bissar-Tadmouri, N., Rochelle, J.,
Dadali, E. L., et al. (2004). Mutations in the mitochondrial GTPase mitofusin
2 cause Charcot-Marie-Tooth neuropathy type 2A. Nat. Genet. 36, 449–451.
doi: 10.1038/ng1341
Conflict of Interest Statement: The Review Editor Silvia Campello declares that,
despite being affiliated to the same institution as authors Alessia Mirra and Maria
Teresa Carrì, the review process was handled objectively and no conflict of interest
exists. The authors declare that the research was conducted in the absence of any
commercial or financial relationships that could be construed as a potential conflict
of interest.
Received: 02 December 2014; accepted: 19 January 2015; published online: 10 February
2015.
Citation: Cozzolino M, Rossi S, Mirra A and Carrì MT (2015) Mitochondrial
dynamism and the pathogenesis of Amyotrophic Lateral Sclerosis. Front. Cell. Neurosci.
9:31. doi: 10.3389/fncel.2015.00031
This article was submitted to the journal Frontiers in Cellular Neuroscience.
Copyright © 2015 Cozzolino, Rossi, Mirra and Carrì. This is an open-access article
distributed under the terms of the Creative Commons Attribution License (CC BY).
The use, distribution and reproduction in other forums is permitted, provided the
original author(s) or licensor are credited and that the original publication in this
journal is cited, in accordance with accepted academic practice. No use, distribution
or reproduction is permitted which does not comply with these terms.
Frontiers in Cellular Neuroscience www.frontiersin.org February 2015 | Volume 9 | Article 31 | 5
